BioCentury | Oct 24, 2020
Product Development

Infusion confusion: the rollout of mAbs for COVID-19 could be chaotic

FDA could soon grant emergency use authorization to one or more COVID-19 monoclonal antibodies. Rather than being celebrated for creating lifelines that could keep hundreds of thousands of Americans out...
BioCentury | Mar 31, 2020
Politics, Policy & Law

FDA’s authorization of malaria drugs for COVID-19 looks like political science

FDA’s decision to grant Emergency Use Authorization for hydroxychloroquine and chloroquine to treat COVID-19 was unnecessary and unwise. The EUA was unnecessary because the drugs are approved in the U.S. to treat malaria and for...
BioCentury | Nov 8, 2019
Product Development

NIDA pushes for translational solutions to opioid crisis

One outcome of the flood of attention to the opioid crisis is that it is starting to sway the perception of addiction towards the concept it is a disease, suffered by patients, rather than a...
BioCentury | Oct 25, 2019
Product Development

Lykera takes aim at aggressive cancers by targeting pre-metastatic niche

...Matrix metalloproteinase 9 PD-L1 (B7-H1; CD274) - Programmed cell death 1 ligand 1 RAGE - Receptor for advanced glycation endproducts...
...Tumor necrosis factor VEGF-A - Vascular endothelial growth factor A Inhua Muijrers-Chen, Associate Editor Matrix metalloproteinase 9 (MMP9) Receptor for advanced glycation endproducts (RAGE) S100...
BioCentury | Apr 19, 2019
Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

...RIP1) Denali Therapeutics Inc. (NASDAQ:DNLI) / Sanofi (Euronext:SAN; NASDAQ:SNY) DNL747 ALS, AD Ph Ib Other Receptor for advanced glycation endproducts (RAGE)...
...vTv Therapeutics Inc. (NASDAQ:VTVT) Azeliragon AD in patients with Type II diabetes Ph II/III (A) RAGE...
...kappa light polypeptide gene enhancer in B cells 1 (NF-kB) (NFKB1) (p105) (p50) Phosphodiesterase-4 (PDE-4) Progranulin (PGRN) (PCDGF) Receptor for advanced glycation endproducts (RAGE) Receptor-interacting...
BioCentury | Dec 6, 2018
Politics & Policy

Bipartisan bill would revamp diagnostics regulation

Champions of legislation in Congress to overhaul diagnostics legislation released a draft bill Thursday that scraps many features of a draft bill released last year and incorporates a different approach proposed by FDA. If it...
BioCentury | Nov 9, 2018
Politics, Policy & Law

Buckle-up, turbulence ahead in Washington

...it must conduct. Must-pass legislation, especially spending bills, will provide a vehicle for turning political rage...
...mobilize effective opposition. Must-pass legislation, especially spending bills, will provide a vehicle for turning political rage...
BioCentury | Jun 15, 2018
Clinical News

vTv to propose path forward for AD candidate despite Phase III miss

...patients. In April, vTv said it would discontinue clinical trials of the oral small molecule receptor for advanced glycation endproducts (RAGE)...
...High Point, N.C. Product: Azeliragon (TTP488) Business: Neurology Molecular target: Receptor for advanced glycation endproducts (RAGE) Description: Oral small molecule RAGE...
...Inventory (ADCS-ADL) Status: Additional Phase III data Milestone: NA Jaime De Leon azeliragon (TTP488, PF-04494700, PF-4494700) vTv Therapeutics Inc. Receptor for advanced glycation endproducts (RAGE)...
BioCentury | Apr 13, 2018
Clinical News

vTv's azeliragon misses Alzheimer’s endpoint

...any "potential benefits or future uses and applications." The product is an oral small molecule receptor for advanced glycation endproducts (RAGE)...
...High Point, N.C. Product: Azeliragon (TTP488) Business: Neurology Molecular target: Receptor for advanced glycation endproducts (RAGE) Description: Oral small molecule RAGE...
...Daily Living Inventory (ADCS-ADL) Status: Phase III discontinued Milestone: NA Brian Moy azeliragon (TTP488, PF-04494700, PF-4494700) vTv Therapeutics Inc. Receptor for advanced glycation endproducts (RAGE)...
BioCentury | Apr 9, 2018
Clinical News

vTv's azeliragon misses Alzheimer’s endpoint

...any "potential benefits or future uses and applications." The product is an oral small molecule receptor for advanced glycation endproducts (RAGE)...
...GK) activator. vTv was off $0.16 to $3.26 on Monday. Brian Moy azeliragon (TTP488, PF-04494700, PF-4494700) vTv Therapeutics Inc. Receptor for advanced glycation endproducts (RAGE)...
Items per page:
1 - 10 of 98